Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CARsgen Awarded US Orphan Drug Status for BCMA CAR-T Candidate

publication date: Sep 3, 2019

Shanghai's CARsgen Therapeutics has been granted US orphan drug designation for its fully human anti-BCMA (B Cell Maturation Antigen) CAR-T cell therapy as a multiple myeloma treatment. The company was approved to start US trials of the candidate in June 2019 and China trials in early 2019. In the Phase I China trial, CARsgen administered CT053 to 24 heavily pre-treated patients: 79.2% showed a complete response and no patient experienced cytokine release syndrome (CRS) higher than grade 2. Founded in 2014, CARsgen focuses on CAR-T drug development. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital